AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Study compares weekly dosing efficacies of Fosamax and Actonel.
2004 OCT 18 - (NewsRx.com & NewsRx.net) -- Fosamax Once Weekly (alendronate sodium) increased bone mineral density (BMD) more than Actonel Once-a-Week (risedronate) with similar tolerability, according to results of the Fosamax Actonel Comparison Trial (FACT) .
This is the first U.S. head-to-head study comparing U.S. Food and Drug Administration-approved once-weekly osteoporosis treatments in postmenopausal women with osteoporosis.
In this study, Fosamax provided greater increases in BMD at all sites measured as early as 6 months, and lowered levels of biochemical markers of bone turnover further within the normal pre-menopausal range than Actonel within 3 months. Reducing and stabilizing bone turnover, which leads to increased bone density, are important factors in improving bone strength in patients with osteoporosis.
The results of FACT, which was a 12-month study, were announced online on September 28, 2004, in the Journal of Bone and Mineral Research and were presented on October 1, 2004, at the American Society for Bone Mineral Research meeting in Seattle, Washington. A 12-month extension of this double-blind study, and a second similarly designed study, are currently underway.
Fosamax is the only medicine approved by the U.S. Food and Drug Administration for the treatment of osteoporosis to reduce the risk of both spine and hip fractures in postmenopausal women. Fosamax is the most prescribed medicine for the treatment of osteoporosis, according to Merck, which makes the drug.
"In this 12 month study, Fosamax demonstrated greater increases in BMD and reductions in bone turnover and similar tolerability compared to Actonel," said Marc Hochberg, MD, professor of medicine and epidemiology and Preventive Medicine at the University of Maryland-School of Medicine in Baltimore. "Studies like FACT, that make direct 'head-to-head' comparisons between treatments, are important because they provide important information to clinicians for use in making treatment decisions for postmenopausal women with osteoporosis."
Fosamax showed greater increases in BMD at all pre-specified study endpoints compared to Actonel. Study results showed that Fosamax increased BMD 62% more than Actonel at the hip trochanter, a specific region of the hip, at 12 months (3.4% increase for Fosamax vs. 2.1% for ...
- New Study Comparing Weekly Osteoporosis Treatments Shows FOSAMAX Demonstrated...
- Press release article from: Business Wire September 28, 2004 700+ words
...range than Actonel within three...stabilizing bone turnover, which leads...reductions in bone turnover and similar...compared to Actonel," said Marc...Weekly to Actonel 35 mg Once...Week on BMD, bone turnover and tolerability...
- Postmenopausal Women With Osteoporosis Treated With Actonel for Five Years Have...
- Press release article from: PR Newswire October 4, 2004 700+ words
...the rate of bone turnover increases and...to baseline, Actonel significantly...demonstrating that Actonel returns bone turnover to normal premenopausal...bone in the Actonel-treated group...reduction of bone turnover markers. The...
- The U.S. Food and Drug Administration Approves Actonel for Broader Use in Men...
- Press release article from: PR Newswire August 14, 2006 700+ words
...postmenopausal women. The approval of Actonel for men with osteoporosis...treated with once-a-week Actonel 35 mg experienced statistically...significant reductions in bone turnover markers were achieved at all...3, 6, 12 and 24 months. Actonel was well tolerated, and adverse...
- New Data Show Actonel(R) Reduced Clinical Vertebral Fractures In As Early as...
- Press release article from: PR Newswire October 13, 2001 700+ words
...effective treatment, like Actonel, to stop the fracture cascade...Previous studies have shown Actonel therapy to quickly reduce...meeting today suggest that bone turnover markers may be an alternative...osteoporosis therapies. About Actonel (R) (risedronate sodium...
- Actonel and Fosamax Formulary Evaluation. (Drug Criteria & Outcomes[TM]).
- Newspaper article from: Drug Utilization Review Ball, Travis February 1, 2002 700+ words
...Description Alendronate (Fosamax) and risedronate (Actonel) are bisphosphonates used to increase bone mineral...preferentially localizing resorption sites of active bone turnover. Normal doses have been shown to inhibit bone resorption...
- Actonel Significantly Reduced Osteoporotic Fractures in High-Risk...
- Press release article from: PR Newswire February 10, 2003 700+ words
...published data show that treatment with 5 mg Actonel(R) (risedronate sodium tablets) daily...percent, respectively, at one year with Actonel compared with placebo. The analysis of...that the fracture reduction benefits of Actonel in patients at higher risk of fracture...
- Actonel(R) Provides Low Incidence of Vertebral Fracture in Osteoporosis...
- Press release article from: PR Newswire June 19, 2003 700+ words
In a long-term clinical trial of Actonel(R) (risedronate sodium tablets...safety profile and sustained efficacy of Actonel in the treatment of postmenopausal osteoporosis...postmenopausal women. One group received Actonel 5 mg daily for 7 years; the other received...
- Actonel Significantly Reduced Moderate and Severe Vertebral Fractures By 70...
- Press release article from: PR Newswire September 20, 2002 700+ words
...Research (ASBMR) showed that a 5 mg dose of Actonel(R) (risedronate sodium tablets) daily...analysis combined data from two large Actonel clinical trials, VERT-NA and VERT...fracture at one year in women who received Actonel or placebo. Fracture severity was determined...
Source: HighBeam Research, Study compares weekly dosing efficacies of Fosamax and Actonel.